Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i).

Hussein A TawbiCaroline RobertJan C BraseDaniel GusenleitnerEduard GasalJames GarrettAlexander SavchenkoGüllü GörgünKeith T FlahertyAntoni RibasReinhard DummerDirk SchadendorfGeorgina V LongPaul D NathanPaolo Antonio Ascierto

Published in: Journal for immunotherapy of cancer (2022)

NCT02967692.

Keyphrases

wild type
double blind
skin cancer
metastatic colorectal cancer
phase iii
placebo controlled
clinical trial
randomized controlled trial
basal cell carcinoma